Sanjivani Paranteral Ltd Stock Price Today (NSE: SANJIVIN)
Fundamental Score
Sanjivani Paranteral Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Sanjivani Paranteral Ltd share price today is ₹159.60, down 3.86% on NSE/BSE as of 4 August 2026. Sanjivani Paranteral Ltd (SANJIVIN) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹173.08 (Cr). The 52-week high for SANJIVIN share price is ₹268.80 and the 52-week low is ₹126.00. At a P/E ratio of 25.87x, SANJIVIN is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 15.51% and a debt-to-equity ratio of 0.30.
Sanjivani Paranteral Ltd Share Price Chart — NSE/BSE Historical Performance
Sanjivani Paranteral Ltd share price chart: 9.68% return over the past month. 52-week high ₹268.80, 52-week low ₹126.00.
Sanjivani Paranteral Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹166.00 | ₹174.00 | ₹156.70 | ₹164.85 | 17.59K (Cr) | |
| ₹168.90 | ₹168.90 | ₹160.00 | ₹162.60 | 1.16K (Cr) | |
| ₹161.00 | ₹179.95 | ₹150.55 | ₹160.65 | 6.60K (Cr) | |
| ₹174.00 | ₹175.00 | ₹162.15 | ₹165.70 | 5.49K (Cr) | |
| ₹150.00 | ₹174.95 | ₹150.00 | ₹170.70 | 48.52K (Cr) | |
| ₹149.00 | ₹152.00 | ₹148.00 | ₹150.20 | 10.34K (Cr) | |
| ₹148.25 | ₹174.00 | ₹145.50 | ₹148.55 | 10.47K (Cr) | |
| ₹141.05 | ₹148.00 | ₹140.00 | ₹147.20 | 2.23K (Cr) | |
| ₹144.05 | ₹146.00 | ₹144.00 | ₹145.75 | 1.07K (Cr) | |
| ₹144.55 | ₹147.75 | ₹140.00 | ₹142.30 | 29.91K (Cr) |
Sanjivani Paranteral Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹166.00 | ₹174.00 | ₹156.70 | ₹164.85 | -0.69% | |
| ₹151.30 | ₹179.95 | ₹137.10 | ₹162.60 | +7.47% | |
| ₹157.95 | ₹159.90 | ₹137.00 | ₹154.70 | -2.06% | |
| ₹156.00 | ₹171.85 | ₹126.00 | ₹145.55 | -6.70% | |
| ₹140.00 | ₹186.00 | ₹139.95 | ₹160.00 | +14.29% | |
| ₹182.15 | ₹195.00 | ₹132.50 | ₹132.75 | -27.12% | |
| ₹179.00 | ₹229.00 | ₹161.00 | ₹192.15 | +7.35% | |
| ₹227.00 | ₹244.00 | ₹169.00 | ₹178.40 | -21.41% | |
| ₹192.85 | ₹243.95 | ₹190.00 | ₹231.55 | +20.07% | |
| ₹210.75 | ₹218.00 | ₹170.00 | ₹187.50 | -11.03% | |
| ₹221.50 | ₹233.00 | ₹193.00 | ₹210.75 | -4.85% | |
| ₹260.00 | ₹268.00 | ₹220.00 | ₹221.75 | -14.71% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Sanjivani Paranteral Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Sanjivani Paranteral Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SANJIVIN across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Strong Return on Equity (15.51%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (18.00%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 25.87 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Conservative Debt Levels (D/E: 0.30)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (12.89x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Profit Decline Concern (-74.89%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-27.34%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Institutional Interest (FII+DII: 6.03%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Sanjivani Paranteral Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Sanjivani Paranteral Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Sanjivani Paranteral LtdSanjivani Paran...Selected✓ SANJIVIN • 531569 | 15.6/100 | ₹159.60₹160 | ₹173.08₹173.08 | 25.87Average 25.9 Average | 15.51%Good 15.51% Good | 18.00%Good 18.00% Good | 0.30Excellent 0.3 Excellent | — — | — — | 0.35% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Sanjivani Paranteral Ltd PE Ratio History
Historical price-to-earnings ratio for SANJIVIN — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹5.28 | ₹388.45 | 73.6x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Sanjivani Paranteral Ltd Quarterly Performance
Latest quarterly metrics for SANJIVIN — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-27.34%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-74.89%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Sanjivani Paranteral Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for SANJIVIN — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Sanjivani Paranteral Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Sanjivani Paranteral Ltd (SANJIVIN) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Sanjivani Paranteral Ltd
About SANJIVIN (Sanjivani Paranteral Ltd)
Sanjivani Paranteral Ltd is a dynamic pharmaceutical manufacturer rooted in India, dedicated to crafting essential medicines that address a broad spectrum of health needs. The comp...any's core competency lies in the production of high-quality pharmaceutical formulations, delivered through a diverse range of administration routes. These include meticulously crafted oral solid dosages, guaranteeing ease of use and consistent therapeutic effects, alongside precision-engineered small volume parenterals, enabling rapid and targeted drug delivery. Furthermore, Sanjivani Paranteral specializes in sterile powder formulations, ensuring the integrity and efficacy of sensitive medications. The commitment to quality and innovation permeates every stage of their manufacturing process. Sanjivani Paranteral's therapeutic focus extends across a multitude of critical healthcare domains. The company provides medications for central nervous system disorders, contributing to the management of neurological conditions and mental well-being. They also produce treatments for cardiovascular ailments, aiding in the prevention and control of heart-related diseases. Their antibiotic range combats bacterial infections, while their gastroenterological products support digestive health. Addressing the growing prevalence of diabetes, Sanjivani Paranteral offers anti-diabetic medications, and they also supply anti-allergic formulations to alleviate allergic reactions. This comprehensive approach reflects the company’s dedication to meeting the diverse healthcare demands of the population. Beyond its core product lines, Sanjivani Paranteral demonstrates a commitment to diversifying its offerings and adapting to evolving patient needs. The company manufactures soft gelatin capsules, including those packed with multivitamins, providing a convenient way to supplement dietary deficiencies and promote overall wellness. In the topical arena, they formulate corticosteroids, antiseptics, nonsteroidal anti-inflammatory drugs (NSAIDs), and anti-bacterial creams and ointments, addressing a wide array of skin conditions and infections. Their range also extends to nasal sprays, providing targeted relief for nasal congestion and allergies. This broad portfolio underscores Sanjivani Paranteral's dedication to providing comprehensive healthcare solutions.
Company Details
Key Leadership
Corporate Events
Latest News
SANJIVIN Share Price: Frequently Asked Questions
What is the current share price of Sanjivani Paranteral Ltd?
Sanjivani Paranteral Ltd (SANJIVIN) trades at ₹159.60 on NSE and BSE. Market cap ₹173.08 (Cr). Educational data only.
What is the P/E ratio of Sanjivani Paranteral Ltd?
Sanjivani Paranteral Ltd has a P/E of 25.87x vs industry average 34.89x.
What is the Bull Run score for Sanjivani Paranteral Ltd?
Sanjivani Paranteral Ltd has a Bull Run score of 15.6/100 based on 25+ financial parameters.
Does Sanjivani Paranteral Ltd pay dividends?
Sanjivani Paranteral Ltd has a dividend yield of 0.35%. Past dividends don't guarantee future payments.
What is the ROE of Sanjivani Paranteral Ltd?
Sanjivani Paranteral Ltd has ROE of 15.51%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Sanjivani Paranteral Ltd?
Sanjivani Paranteral Ltd has debt-to-equity of 0.30.
Is Sanjivani Paranteral Ltd a good investment?
Bull Run gives Sanjivani Paranteral Ltd a score of 15.6/100. This is not investment advice — consult a SEBI-registered advisor.